47141-42-4

Basic information

• Product Name: LEVOBUNOLOL
• Synonyms: LEVOBUNOLOL;[(-)-5-[3,(t-Butylamino)-2-hydroxy-propoxy]-3,4-di,HCl;5-[(2S)-3-[(1,1-Dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-1(2H)-naphthalenone;5-[(S)-3-[(1,1-Dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydronaphthalen-1(2H)-one;5-[3-(tert-Butylamino)-2β-hydroxypropyloxy]-3,4-dihydronaphthalen-1(2H)-one;(S)-5-[3-[(1,1-DiMethylethyl)aMino]-2-hydroxypropoxy]- 3,4-dihydro-1(2H)-naphthalenone;l-Bunolol;W 6421A
• CAS NO: 47141-42-4
• Molecular Formula: C17H25NO3
• Molecular Weight: 291.39
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 47141-42-4.mol
• Article Data: 9

Chemical Properties

• Melting Point: 209-211°C
• Appearance: white to pink powder
• Storage Temp.: -20?C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: LEVOBUNOLOL(CAS DataBase Reference)
• NIST Chemistry Reference: LEVOBUNOLOL(47141-42-4)
• EPA Substance Registry System: LEVOBUNOLOL(47141-42-4)

Safety Data

• Hazardous Substances Data: 47141-42-4(Hazardous Substances Data)

Usage

Description

Levobunolol, also known as its hydrochloride salt, is a cyclic ketone with a 3,4-dihydronaphthalen-1-one structure, substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). It is a non-selective beta-adrenergic antagonist, which means it can block the action of adrenaline on both beta-1 and beta-2 receptors. Levobunolol is a white solid and is available under the brand names Akbeta (Akorn) and Betagan (Allergan).

Uses

Used in Ophthalmology:
Levobunolol is used as an antiglaucoma agent in ophthalmic solutions. It helps to reduce the intraocular pressure in the eyes, which is a common treatment for glaucoma. By decreasing this pressure, the risk of optic nerve damage and vision loss is reduced.
Used in Neurology:
As a non-selective adrenoceptor antagonist, Levobunolol is used as an anticonvulsant. It works by blocking the action of adrenaline on the adrenoceptors, which can help to prevent or reduce the severity of seizures in patients with epilepsy or other seizure disorders.

Originator

Betagan,Allergan,India

Therapeutic Function

Beta-adrenergic blocker

InChI:InChI=1/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3/t12-/m0/s1

Upstream product

• 28315-93-7 5-Hydroxy-1-tetralone 
• 75-64-9 tert-butylamine 
• 106-89-8 epichlorohydrin 

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

FLUORESCENCE BASED DETECTION OF SUBSTANCES

A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.

Reversible gelation emulsion compositions and methods of use

Reversibly gelling aqueous and oil emulsions are disclosed which can be modified to incorporate oil soluble pharmaceutical compounds for delivery to physiological systems in a soluble form and which undergo significant changes in viscosity in response to substantially simultaneous changes in both temperature and pH. The compositions are formed of relatively low concentrations of a stable combination of at least one pH-sensitive reversibly gelling polymer, at least one temperature-sensitive reversibly gelling polymer and at least one organic oil. The compositions can be formulated to exhibit a sol-gel transition over a wide range of conditions and viscosities and may be modified to incorporate a pharmaceutical compound for utilization as droppable or injectable drug delivery systems which will gel following administration to a physiological system for the sustained delivery of such pharmaceutical compounds.